356
Backers in a recent round
287 added at least one new company in this market. The remainder participated only in companies they had already backed here.
Explore recently active backers ↗MARKET NOTES / 001UNITED STATES / CAMBRIDGE / LIFE SCIENCES
LESS GUESSWORK. A BETTER RESEARCH LIST.Life Sciences.
Life Sciences.
Cambridge.
Map the capital.
Find your next conversation.
Who backs this market, where they enter, and how recently they have added a new company. A directory built around the questions founders actually ask.
Build your research shortlist ↘Companies are based in Cambridge · investors can be based anywhere
Dataset through 22 May 2026 · calculated 14 Sep 2026
01 / THE SHORTLIST LAB
Make the list work for your company.
23 backers based in Cambridge are shown by default. Compare up to three.
A CLOSER LOOK AT WHERE
Find investors in your preferred location.
Search a recorded city, country or neighbourhood among the backers of this market.
Five location searches per day. Results use recorded locations; some investors have city-level coverage only.
23 of 637 selected backers · Cambridge only
Shows investors whose recorded city is Cambridge. Unknown cities are excluded. Market charts cover all investor locations.
Theme filtering selects backers of companies carrying that theme tag. Entry-stage filtering selects backers with an entry at that stage; the two matches may be different companies. Row metrics describe their entire dated Life Sciences history in Cambridge.
Your side-by-side comparison
Lead flags and later investments may be incompletely recorded. Repeat counts are not adjusted for time since entry.
| Compare | Investor / recorded location | Companies here | New in 24 months | Median total entry round | Companies backed again | Latest investment |
|---|---|---|---|---|---|---|
| Loading investors… | ||||||
No backers match these filters. Broaden the theme, location, entry stage or activity window.
02 / THE MARKET READActivity is a better starting point
Activity is a better starting point
than a long list of names.
Latest 24 months: after 22 May 2024 through 22 May 2026.
100
Distinct equity rounds
Across 87 companies, versus 152 rounds in the preceding 24 months. Each company round is counted once.
See the recent evidence ↗18%
Rounds at Angel, Pre-Seed or Seed
18 of 100 recent rounds. Compare your stage with its own financing range before sizing the ask.
Compare stage ranges ↗69%
Participations were first entries
367 first investor–company relationships out of 532 participations. The other 165 were later rounds together.
Find backers adding companies ↗Build a syndicate beyond the city.
Of 356 recently active backers, 11 have a recorded Cambridge location and 304 are based elsewhere. Location is missing for 41. Search by market experience first, then investigate the people and their remit.
Match the whole round to your plan.
Recent Seed rounds have a median size of $7.9M, across 16 disclosed amounts. That is total company financing. An individual investor’s cheque or available capital is not disclosed here.
03 / EMERGING THEMES
Which themes are gaining share?
Follow financing activity across the company classifications represented in this market.
Latest four complete quarters: 01 Apr 2025–31 Mar 2026 · 49 market rounds, versus 55 in the preceding four quarters.
Biopharmaceuticals
+6.5 pp29 of 49 recent rounds (59.2%), versus 29 of 55 (52.7%).
Oncology
+5.8 pp18 of 49 recent rounds (36.7%), versus 17 of 55 (30.9%).
Deep Tech
41.7%5 of 12 rounds in Q1 2025, compared with 21.1% over the prior four quarters.
Genomics
25.0%3 of 12 rounds in Q1 2025, compared with 14.0% over the prior four quarters.
SPIKE DETECTION
Look beyond the headline total.
Share of market roundsPrior four-quarter shareDetected spike
Scroll sideways to explore all quarters.
Q1 2026 · 3 of 13 market rounds · 3 companies · 23.1% share. A detected spike, 2.77× the prior four-quarter share.
Select a dot to inspect the exact count and baseline. The partial quarter through 22 May 2026 is shown but cannot trigger a spike.
The theme shift, year by year.
Share of all recorded Life Sciences rounds in Cambridge. Each cell also gives its theme-round count.
| Investment theme | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026* |
|---|---|---|---|---|---|---|---|
| 64.8%68 / 105 | 55.4%62 / 112 | 53.3%40 / 75 | 58.8%47 / 80 | 63.2%36 / 57 | 54.2%26 / 48 | 57.1%12 / 21 | |
| 41.0%43 / 105 | 40.2%45 / 112 | 40.0%30 / 75 | 30.0%24 / 80 | 35.1%20 / 57 | 31.3%15 / 48 | 42.9%9 / 21 | |
| 33.3%35 / 105 | 29.5%33 / 112 | 29.3%22 / 75 | 25.0%20 / 80 | 21.1%12 / 57 | 29.2%14 / 48 | 9.5%2 / 21 | |
| 28.6%30 / 105 | 24.1%27 / 112 | 18.7%14 / 75 | 21.3%17 / 80 | 14.0%8 / 57 | 16.7%8 / 48 | 9.5%2 / 21 | |
| 18.1%19 / 105 | 13.4%15 / 112 | 9.3%7 / 75 | 13.8%11 / 80 | 14.0%8 / 57 | 10.4%5 / 48 | 4.8%1 / 21 | |
| 15.2%16 / 105 | 8.9%10 / 112 | 12.0%9 / 75 | 18.8%15 / 80 | 15.8%9 / 57 | 14.6%7 / 48 | 14.3%3 / 21 | |
| 10.5%11 / 105 | 12.5%14 / 112 | 28.0%21 / 75 | 12.5%10 / 80 | 10.5%6 / 57 | 18.8%9 / 48 | 33.3%7 / 21 | |
| 7.6%8 / 105 | 9.8%11 / 112 | 12.0%9 / 75 | 12.5%10 / 80 | 10.5%6 / 57 | 8.3%4 / 48 | 19.1%4 / 21 |
*2026 is partial. Company themes use the tags available in this dataset, applied to historical rounds; they do not date when a business adopted a technology. Themes overlap, so shares do not add to 100%. Each company round is counted once within a theme. These charts cover investors from all locations; the shortlist keeps its own location filter.
How a spike is detected
A complete quarter is flagged when its theme share is at least 1.75× the share across the preceding four quarters and at least 5 percentage points higher. It must contain at least 3 theme rounds across 3 companies, at least 10 market rounds, and at least 3 theme rounds in the baseline. All four baseline quarters must have market observations. A zero baseline, missing observations or partial quarter cannot produce a flag.
This is a transparent screening rule, not a statistical significance test or a forecast. A higher share can accompany fewer rounds when the wider market contracts; the counts beside the chart make that distinction visible.
04 / THE DEPTH MAP
One appearance, or a pattern?
950 of 1,411 backers with dated histories appear in just one company. Select a cell to explore the directory.
| Portfolio breadth here | 1 company | 2 companies | 3–5 | 6–10 | 11+ |
|---|---|---|---|---|---|
| Firms & institutions | |||||
| Individual angels |
Circle area increases with backer count. The shortlist includes backers with 2 or more companies in this market, plus other backers active in the latest 24 months. In the 1-company cell, only recently active backers are available to explore. The shortlist’s investor-location filter also applies; select all locations to broaden the results. 10 backers have only undated entries.
05 / ROUND DESIGN
Different stages. Different capital.
Recent equity rounds · 24-month window.
Amounts are in USD.
StageDistinct roundsMedian / middle half
Seed
18
$7.9M$5.2M–$12M16 disclosed
Series A
29
$51M$15M–$85M26 disclosed
Series B
21
$57M$37M–$105M20 disclosed
Series C
11
$75M$50M–$105M9 disclosed
Series D
8
$123M$48M–$197M8 disclosed
Series E+
5
$35M$27M–$110M5 disclosed
Post-IPO
8
$125M$54M–$191M8 disclosed
06 / FOLLOW THE EVIDENCE
The most recent recorded rounds.
Distinct company rounds.
Named backers are shown lead-first.
Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS
$4.8M total equity round5 named backers
LifeSpan Vision Ventures · Mass General Brigham · Ono Venture Investment · SV Health Investors · UTEC
Developer of messenger ribonucleic acid therapies for immune cell programming
$122M total equity round4 named backers
Hatteras Venture Partners · Newpath Partners · Alexandria Venture Investments · Arch Venture Partners
Developer of oral small molecule inhibitors for treating blood cancers
$220M total equity round1 named backer
Venrock
Developer of single-cell functional analysis using a droplet-based platform
$27M total equity round6 named backers
Arch Venture Partners · Illumina Ventures · Longwall Venture Partners · M Ventures · ND Capital · +1 more
AI-based cancer detection tool for providers
$100M total equity round1 named backer
Flagship Pioneering
Developer of multi-target protein therapeutics for treating solid tumor cancers
$3.1M total equity round3 named backers
BrightEdge · Impact Ventures · Mission BioCapital
07 / READING THE ATLAS
What these patterns can tell you.
The market boundary
Recorded equity rounds for companies tagged Life Sciences and located in Cambridge. Investor headquarters may be elsewhere. Company sector and location reflect the available company records, not necessarily the location or sector at the investment date.
The time boundary
Data coverage ends 22 May 2026. The latest market round is 18 May 2026. There are 29 undated participations, excluded from timing metrics. Activity after the cutoff is unknown.
The relationship boundary
“New” is the first dated relationship between a backer and a company in this market. “Backed again” requires a later dated round together. A first observed entry may follow an earlier unrecorded investment.
The financing boundary
Amounts describe entire equity rounds, not personal cheques, fund capacity or returns. Medians exclude missing and non-positive amounts; the middle half spans the 25th–75th percentiles. A recorded investment does not establish current availability.
Find the businesses
worth a closer look.
Search Cambridge Life Sciences companies in Radar. Filter the company directory to explore the businesses behind your market and investor research.
Explore companies in Radar ↗A research dashboard.
Built for your company.
We build customized research dashboards for companies. Tell us which competitors, markets and questions matter to your team, and discuss a dashboard designed around your needs.
Discuss a custom dashboard ↗A customized service from Fliar. Contact us to discuss your requirements.Turn your questions
into deeper research.
Use Fliar Prism to research a company, market or topic, with reports and insights drawn from its research dataset.
Explore Fliar Prism ↗Start with the company or question you want to understand.Calculated 14 Sep 2026 · 637 investor histories to explore